Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. We are committed to developing therapeutic products that we believe have best-in-class potential, meaning therapeutic candidates that have the potential to be safer and more effective products than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration.
Our lead product development programs utilize MultiStem, a proprietary stem cell product that we believe could be beneficial in the treatment for multiple disease indications in the cardiovascular, neurological, and inflammatory and immune disease areas, as well as certain other conditions. MultiStem is currently being evaluated in several clinical stage programs, as well as a range of preclinical programs. In addition, we are developing novel pharmaceuticals to treat indications such as obesity and related metabolic conditions, as well as certain neurological disorders.
MultiStem utilizes multipotent adult progenitor cells discovered at the University of Minnesota.
Market Capitalization: $44.4M
Current Revenue: Approx $9M from license fees, milestone payments and royalties
Cash Burn: Vicinity of $14M including clinical trials
Cash and Liquid Investments to Current Liabilities: $29M/$4M
Clinical Status: Phase II enrolling - Inflamatory Bowel Disease
Phase I completed - HST/GVHD with Orphan Status
Phase I completed - Acute Myocardial Infarction, Phase II authorized
Phase II enrolling - Ischemic Stroke
Stem Cell Digest Posts - Athersys Inc.
Jan. 2, 2010 - The Year Big Pharma Bought Into Mesenchymal Stem Cell Therapy
March 4, 2010 - Stem Cell Therapy and Scalable Stem Cell Solutions
Comments